Form 8-K - Current report:
SEC Accession No. 0001628280-25-017769
Filing Date
2025-04-15
Accepted
2025-04-15 07:43:27
Documents
15
Period of Report
2025-04-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K advm-20250415.htm   iXBRL 8-K 24682
2 EX-99.1 exhibit991_41525pressrelea.htm EX-99.1 67181
6 logo.jpg GRAPHIC 9327
  Complete submission text file 0001628280-25-017769.txt   236885

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT advm-20250415.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT advm-20250415_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT advm-20250415_pre.xml EX-101.PRE 12508
17 EXTRACTED XBRL INSTANCE DOCUMENT advm-20250415_htm.xml XML 2889
Mailing Address 100 CARDINAL WAY REDWOOD CITY CA 94063
Business Address 100 CARDINAL WAY REDWOOD CITY CA 94063 (650) 649-1004
Adverum Biotechnologies, Inc. (Filer) CIK: 0001501756 (see all company filings)

EIN.: 205258327 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36579 | Film No.: 25837584
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)